Table 5.

Patient-reported measures for HCV+ versus HCV− patients (DOPPS phases 1–5, 1996–2015): Linear regression models

Quality of Life Measure (Higher=Better)Outcome MeanUnadjusted Difference (95% CI)aAdjusted Difference (95% CI)b
KDQOL-36 Physical Component Summaryc,d36.5−1.2 (−1.5 to −0.8)e−0.9 (−1.2 to −0.5)e
 Physical functioning41.8−2.9 (−4.0 to −1.7)e−2.8 (−3.8 to −1.7)e
 Role-physical38.0−2.0 (−3.2 to −0.9)e−2.1 (−3.2 to −0.9)e
 Bodily pain59.6−5.6 (−6.6 to −4.6)e−3.8 (−4.8 to −2.8)e
 General health40.9−3.3 (−4.1 to −2.5)e−2.6 (−3.5 to −1.8)e
KDQOL-36 Mental Component Summaryc,d44.7−1.2 (−1.6 to −0.8)e−1.2 (−1.6 to −0.8)e
 Vitality38.8−2.4 (−3.3 to −1.5)e−2.3 (−3.2 to −1.4)e
 Social functioning58.3−2.5 (−3.5 to −1.5)e−1.9 (−3.0 to −0.9)e
 Role-emotional54.1−2.7 (−3.9 to −1.4)e−3.3 (−4.5 to −2.0)e
 Mental health62.8−2.9 (−3.7 to −2.2)e−2.2 (−3.0 to −1.5)e
KDQOL-36 Kidney Disease Burdenc,d36.7−1.8 (−2.6 to −1.0)e−2.1 (−3.0 to −1.3)e
  • HCV+, hepatitis C virus-positive; HCV−, hepatitis C virus-negative; DOPPS, Dialysis Outcomes and Practice Patterns Study; 95% CI, 95% confidence interval; KDQOL-36, Kidney Disease Quality of Life instrument.

  • a Adjusted for DOPPS country (United States black and nonblack patients considered separately) and phase and accounting for facility clustering.

  • b Additionally adjusted for age, sex, time on dialysis, 13 summary comorbidities and hepatitis B infection, and albumin, phosphorus, and creatinine levels.

  • c Parameter estimates from linear mixed models represent the modeled difference between HCV+ versus HCV− patients (n=44,320 patients; the models for the subscales had additional patients that did not complete all of the questions necessary to calculate the summary scores, n=50,771–53,576); n=53,596 patients completed the Kidney Disease Burden questions.

  • d Physical and mental component summary and kidney disease burden scores calculated from the KDQOL-36; Lower kidney disease burden score indicates more kidney disease burden. Parameter estimate is from a linear mixed model and represents the modeled difference between HCV+ and HCV− patients (n=44,320 patients).

  • e P<0.05.